RxDoctor Payments Data

Trung Tran, MD

Internal Medicine · Norcross, GANPI 1932202983

Payments from drug & device makers

$801in general payments, 2019–2025

Across 37 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$214
  • Amgen$116
  • Gilead$96
  • Fujifilm Wako Diagnostics U.S.A. Corporation$94
  • GSK$85
  • AstraZeneca$80
  • plus $117 from 4 others

What the payments were for

  • Food & beverage$801100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk13$214
Amgen7$116
Gilead1$96
Fujifilm Wako Diagnostics U.S.A. Corporation1$94
GSK4$85
AstraZeneca4$80
Boehringer Ingelheim2$35
Exact Sciences2$31
Kowa Pharmaceuticals America, Inc.2$28
Lilly USA, LLC1$23

How this compares

$801 in reported general payments places this provider in the 60th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$63,762
Medicare patients
124
Services billed
927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin128$199,775
ProliaDenosumab46$79,658
JanuviaSitagliptin Phosphate44$61,983
FarxigaDapagliflozin Propanediol45$53,437
JanumetSitagliptin Phos/Metformin Hcl36$46,759
TradjentaLinagliptin34$41,789
TrulicityDulaglutide20$20,542
GlyxambiEmpagliflozin/Linagliptin12$20,444
VascepaIcosapent Ethyl48$20,395
SymbicortBudesonide/Formoterol Fumarate32$11,721
EliquisApixaban14$8,191
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,757
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,520
Diclofenac Sodium186$6,934
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$35$262,009174 claims
AmgenProlia$116$79,65846 claims
AstraZenecaFarxiga, Symbicort$80$65,15877 claims
Lilly USA, LLCTrulicity$23$20,54220 claims
GSKTrelegy Ellipta, Anoro Ellipta$85$14,66726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Norcross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →